Plasma biomarker and machine learning modeling of clinical progression in cognitively normal individuals at risk for Alzheimer's disease.
AIMS To evaluate whether plasma biomarkers can distinguish cognitively normal (CN) individuals who remain clinically stable from those who subsequently develop mild cognitive impairment (MCI) or Alzheimer's disease (AD) and to test the predictive performance of classification data‑driven models. MATERIALS AND METHODS...